Atypical antipsychotics part I: Pharmacology, pharmacokinetics, and efficacy

Annals of Pharmacotherapy

Volumn 33, Issue 1, 1999, Pages 73-85

  Markowitz, John S ^a   Brown, Candace S ^b   Moore, Thea R ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; Conventional antipsychotics; Extrapyramidal effects; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM;

EID: 0032950969     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17215     Document Type: Review

References (87)

1. Green AI. Brown WA. Prolactin and neuroleptic drugs. Neurol Clin 1988:6:213-23.
2. Kane JM. Current problems with the pharmacotherapy of schizophrenia. Clin Neuropharmacol 1995:18(suppl 1):S154-61.
3. Risch SG. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 1996:16(suppl):11S-4S.
4. Richelson E. Preclinical pharmacology ofneuroleptics: focus on new generation compounds. J Clin Psychiatry 1996:57(suppl 11):4-11.
5. Kane JM. Schizophrenia. N Engl J Med 1996:334:3441.
6. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993:16:589-610.
7. Borison RL. Diamond BI. Neuropharmacology of the extrapyramidal system. J Clin Psychiatry 1987:48(suppl):7-12.
8. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990:40:222-47.
9. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996:153:466-76.
10. Kinon BJ. Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996:124:2-24.
11. 2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996:124:35-9.
12. Kane J. Honigfield G. Singer J. Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988:45:789-96.
13. Lindenmayer J-P. Grochowski S. Mabugut L. Clozapine effects on positive and negative symptoms: a six month trial in treatment-resistant schizophrenics. J Clin Pychopharmacol 1994:14:201-4.
14. 1 values. J Pharmacol Exp Ther 1989:25:238-46.
15. Robertson A. MacDonald C. Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmacol Biochem Behav 1984:21:97-101.
16. Roth BL. Meltzer HY. The role of serotonin in schizophrenia. In: Bloom FE. Kupfer DJ. eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press. 1995:1215-28.
17. Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996:129:23-31.
18. Marder SR. Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994:151:825-35.
19. Peusken J. Risperidone in the treatment of patients with chronic schizophrenia in a multinational, multicentre, double-blind, placebo-group study versus haloperidol. Br J Psychiatry 1995:166:712-26.
20. Baldessarini RJ. Rankenburg FR. Clozapine: a novel antipsychotic medication. N Engl J Med 1991:324:746-54.
21. Alvir JM. Lieberman JA. Schaff JA. Clozapine-induced agranulocytosis, incidence and risk factors in the United States. N Engl J Med 1993:329: 162-7.
22. Tandon R. Kane JM. Neuropharmacological basis of clozapine's unique profile. Arch Gen Psychiatry 1993:50:157-9.
23. Arnt J. Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998:18:63-101.
24. Jann M. Grimsley S. Gray E. Chang W. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993:24:161-76.
25. 1c. receptor antagonists. Eur J Pharmacol 1993:245:179-82.
26. Prescribing information. Zyprexa (olanzapine). Indianapolis, IN: Eli Lilly, 1997.
27. Schotte A. Jansen PFM. Gommeren W. Luyten WHML. Van Compel P. Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996:124:57-73.
28. Hirsch SR, Link CGG, Goldstein JM. Arvanitis LA. ICI 204.636: a new atypical antipsychotic dnig. Br J Psychiatry 1996:168(suppl 29):45-56.
29. Janicak PG, Davis JM. Preskorn SH, Ayd FJ. Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins. 1997:168-9.
30. Byerly MJ. DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996:16:177-87.
31. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996:57(suppl 11):12-25.
32. Jann MW, Lam YW, Chang WH. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch Int Pharmacodyn Ther 1994:328:243-50.
33. 3-bei der metabolisierung des clozapins im menschlichen korper. Arzneimittelforschung 1977:27:982-90.
34. Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis, 1997.
35. Pitner JK, Mintzer JE. Pennypacker LC. Jackson CW. Efficacy and adverse effects of clozapine in four elderly patients. J Clin Psychiatry 1995:56:180-5.
36. Cooper TB. Clozapine plasma level monitoring: current status. Psychiatr Q 1996:67:297-311.
37. Cardoni AA. Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 1995:29:610-8.
38. Grant S. Fitton A. Risperidone a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994:48:253-73.
39. Curtis VA, Kerwin RW. A risk-benefit assessment of risperidone in schizophrenia. Drug Saf 1996:12:139-45.
40. Gupta S, Droney T. Risperidone: once-daily dosage. Ann Clin Psychiatry 1996:8:221.
41. Springfield AC. Bodiford E. An overdose of risperidone. J Anal Toxicol 1996:20:202-3.
42. Bymaster FP. Zalligaro DO. Falcone JF. Marsh RD. Moore NA. Tye NC, et al. Radioreceptor binding profile of the antipsychotic olanzapine. Neuropsychopharmacology 1996:14:87-96.
43. Tamminga CA. Lahti AC. The new generation of antipsychotic drugs. Int Clin Psychopharmacol 1996:11(suppl 2):73-6.
44. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major active metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996:276:658-66.
45. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenie patients. J Clin Psychopharmacol 1997:17:472-7.
46. Hamner MB, Arvanitis LA, Miller BG, Link CGG. Hong WW. Plasma prolactin in schizophrenia subjects treated with Seroquel (M) (ICI 204,636). Psychopharmacol Bull 1996:32:107-10.
47. Prescribing information. Seroquel (quetiapine). Wilmington, DE: Zeneca Pharmaceuticals, 1997.
48. Sakamoto K, Nakamura Y, Aikoh S, Baba T, Perregaard H, Pedersen EK, et al. Metabolism of sertindole: identification of the metabolites of rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica 1995:25:1327-43.
49. Davis R, Markham A, Ziprasidone. CNS Drugs 1997:Aug 8(2):153-9.
50. Guy W. Clinical Global Impression. In: Guy W. ed. ECDEU: Assessment manual for psychopharmacology (DHEW No. (ADM) 76-338). Rockville, MD: National Institute of Mental Health 1962:218-22.
51. Overall JF, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962:10:799-812.
52. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Symptom Scale for Schizophrenics. Psychiatry Res 1988:23:99-110.
53. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa. 1983.
54. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979:134:382-9.
55. Chouinard G, Ross-Chouinard A. Arunable L. Jones BD. The Extrapyramidal Symptoms Rating Scale. Can J Neural Sci 1980:7:233-9.
56. Simpson G, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970:46(suppl 221):11-9.
57. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989:154:672-6.
58. Schooler NR. Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982:39:483-7.
59. Coding Symbol and Thesaurus for Adverse Event Terminology (COSTART). Rockville, MD: US Department of Health and Human Services, 1990.
60. Association for Methodology and Documentation in Psychiatry (Arbeltsgemeinschaft fur methodik und dokumentation in der psychiatrie (AMDP)): Das AMDP-system: Manual zur dokumentation psychiarriacher befunde 4, Berlin, Auflage, 1981.
61. Kane J. Prediction of clozapine response (abstract). 29th Annual Meeting of the New Clinical Drug Evaluation Unit. June 1, 1989, Key Biscayne, FL.
62. Conley RR, Carpenter WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997:154:1243-7.
63. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992:28: 213-8.
64. Chouinard G, Jones B, Remington G, Bloom D. Addington D, Mac-Ewan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993:13:25-40.
65. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol (abstract). Clin Neuropharmacol 1992:15(suppl 1, pt A): 90A-1A.
66. Huttunen MO, Piepponen T, Rantanen H, Larmo I. Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995:91:271-7.
67. Claus A, Bollen J, DeCuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992:85:295-305.
68. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993:88:395-402.
69. Heinrich K, Kleiser E, Lehmann E, Kinzler E. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994:18:129-37.
70. Kleiser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995;15(suppl 1):45S-51S.
71. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998:155:499-504.
72. Beasley C, Tollefson G, Tye N, Moore N. Olanzapine: a potential "atypical" antipsychotic agent. Presented at the 32nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, HI, December 13-17, 1993.
73. Tollefson GD, Clinical experience with long-term continuation treatment with olanzapine. Presented at the World Psychiatric Association Meeting, Madrid, Spain, September 23-28, 1996.
74. Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996:14:111-23.
75. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997:154:457-65.
76. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997:17:407-18.
77. Fabre LF, Arvanitis LA. Pultz J. Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995:17:366-78.
78. Small JG, Hirsch SR, Arvanitis L, Miller BG, Link CGG, Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997:54: 549-57.
79. Borison RL, Arvanitis LA, Miller BG. ICL 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-69.
80. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
81. Targum S, Caputo K, Grebb J, Chung L, Kashkin K. Mendels J. Sertindole treatment of hospitalized schizophrenic patients. First International Congress on Hormones. Brain and Neuropsychopharmacology, Rhodes, Greece, September 1993.
82. Daniel DG, Schmitz PJ, Holgate KL. Two open-label, long-term safety studies of sertindole. Presented at the 156th Annual Meeting of the American Psychiatric Association, New York. May 1996.
83. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91.
84. Reeves KR, Harrigan EP. The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaftective disorder. Presented at the XXth Collegium International Neuropsychopharmacolicum. Melbourne, Australia, June 1996.
85. Harrigan E, Morrissey M, Ziprasidone Working Group. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder. Presented at the XXth Collegium Internationale Neuropsychopharmacologicum, Melbourne, Australia, June 1996.
86. Daniel D, Reeves K, Harrigan EP. The efficacy and safety of ziprasidone 80 mg/day and 160 mg/day in schizophrenia and schizoaffective disorder (abstract). Schizophr Res 1997;24:204.
87. O'Connor R, Harrigan E, Heym J. The efficacy and safety profile of a new antipsychotic, ziprasidone. Presented at the VIIIth Congress of the European College of Neuropharmacology, Venice, Italy, September 1995.